Selling, General, and Administrative Costs: Novartis AG vs Exelixis, Inc.

A Tale of Two Companies: SG&A Expenses Over Time

In the world of pharmaceuticals, managing costs is as crucial as innovation. This chart offers a fascinating glimpse into the Selling, General, and Administrative (SG&A) expenses of two industry players: Novartis AG and Exelixis, Inc., from 2014 to 2023.

Novartis AG: A Steady Giant

Novartis AG, a Swiss multinational, consistently reported SG&A expenses around $14 billion annually, peaking in 2018. Despite a slight decline to $12.5 billion in 2023, Novartis's expenses reflect its expansive global operations.

Exelixis, Inc.: A Rising Star

In contrast, Exelixis, Inc., a smaller biotech firm, saw its SG&A expenses grow nearly tenfold, from $50 million in 2014 to $540 million in 2023. This surge underscores Exelixis's aggressive expansion and investment in market presence.

Conclusion

This comparison highlights the diverse strategies in managing operational costs within the pharmaceutical sector.